In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 3, 2016, Pages 1847-1853

  Cheng, Guofeng ^a   Tian, Yang ^a   Doehle, Brian ^a   Peng, Betty ^a   Corsa, Amoreena ^a   Lee, Yu Jen ^a   Gong, Ruoyu ^a   Yu, Mei ^a   Han, Bin ^a   Xu, Simin ^a   Dvory Sobol, Hadas ^a   Perron, Michel ^a   Xu, Yili ^a   Mo, Hongmei ^a   Pagratis, Nikos ^a   Link, John O ^a   Delaney, William ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; CARRIER PROTEIN; DRUG COMBINATION; FLUORENE DERIVATIVE; NS-5 PROTEIN, HEPATITIS C VIRUS; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; DISEASE COURSE; EC50; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GENETICS; GENOTYPE; HELA CELL LINE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MICROBIAL SENSITIVITY TEST; TUMOR CELL LINE;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; DRUG SYNERGISM; FLUORENES; GENOTYPE; HELA CELLS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MICROBIAL SENSITIVITY TESTS; SOFOSBUVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84960172314     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02524-15     Document Type: Article

References (34)

1. Negro F, Alberti A. 2011. The global health burden of hepatitis C virus infection. Liver Int 31(Suppl 2):S1-S3. http://dx.doi.org/10.1111/j.1478-3231.2011.02537.x.
2. Lavanchy D. 2011. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107-115. http://dx.doi.org/10.1111/j.1469-0691.2010.03432.x.
3. Bourliere M, Oules V, Ansaldi C, Adhoute X, Castellani P. 2014. Sofosbuvir as backbone of interferon free treatments. Dig Liver Dis 46(Suppl 5):S212-S220. http://dx.doi.org/10.1016/j.dld.2014.09.024.
4. Gilead Sciences Inc. 2014. Harvoni (ledipasvir and sofosbuvir) tablets, for oral use. U. S. prescribing information. Gilead Sciences Inc, Foster City, CA.
5. Link JO, Taylor JG, Xu L, Mitchell M, Guo H, Liu H, Kato D, Kirschberg T, Sun J, Squires N, Parrish J, Keller T, Yang ZY, Yang C, Matles M, Wang Y, Wang K, Cheng G, Tian Y, Mogalian E, Mondou E, Cornpropst M, Perry J, Desai MC. 2014. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem 57:2033-2046. http://dx.doi.org/10.1021/jm401499g.
6. Younossi ZM, Stepanova M, Marcellin P, Afdhal N, Kowdley KV, Zeuzem S, Hunt SL. 2015. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1, -2, and -3 clinical trials. Hepatology 61:1798-1808. http://dx.doi.org/10.1002/hep. 27724.
7. Afdhal N, Reddy KR, Nelson DR, Lawitz E, Gordon SC, Schiff E, Nahass R, Ghalib R, Gitlin N, Herring R, Lalezari J, Younes ZH, Pockros PJ, Di Bisceglie AM, Arora S, Subramanian GM, Zhu Y, Dvory-Sobol H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Sulkowski M, Kwo P. 2014. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483-1493. http://dx.doi.org/10.1056/NEJMoa1316366.
8. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Brau N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P. 2014. Ledipasvir and sofosbuvir for untreated HCV genotype1infection. NEngl J Med 370:1889-1898. http://dx.doi.org/10.1056/NEJMoa1402454.
9. Abergel A, Loustaud-Ratti V, Metivier S, Jiang D, Kersey K, Knox SJ, Pang PS, Samuel D, Asselah T. 2015. Ledipasvir/sofosbuvir treatment results in high SVR rates in patients with chronic genotype 4 and 5 HCV infection. J Hepatol 62:S219-S220. http://dx.doi.org/10.1016/S0168-8278 (15) 30070-2.
10. Kim S, Welsch C, Yi M, Lemon SM. 2011. Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III. J Virol 85:6645-6656. http://dx.doi.org/10.1128/JVI.02156-10.
11. Hughes M, Griffin S, Harris M. 2009. Domain III of NS5A contributes to both RNA replication and assembly of hepatitis C virus particles. J Gen Virol 90:1329-1334. http://dx.doi.org/10.1099/vir.0.009332-0.
12. Kwon HJ, Xing W, Chan K, Niedziela-Majka A, Brendza KM, Kirschberg T, Kato D, Link JO, Cheng G, Liu X, Sakowicz R. 2015. Direct binding of ledipasvir to HCV NS5A: mechanism of resistance to an HCV antiviral agent. PLoS One 10:e0122844. http://dx.doi.org/10.1371/journal.pone.0122844.
13. Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. 2012. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol 57:24-31. http://dx.doi.org/10.1016/j.jhep. 2011.12.029.
14. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O'Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465:96-100. http://dx.doi.org/10.1038/nature08960.
15. Hezode C, Hirschfield GM, Ghesquiere W, Sievert W, Rodriguez-Torres M, Shafran SD, Thuluvath PJ, Tatum HA, Waked I, Esmat G, Lawitz EJ, Rustgi VK, Pol S, Weis N, Pockros PJ, Bourliere M, Serfaty L, Vierling JM, Fried MW, Weiland O, Brunetto MR, Everson GT, Zeuzem S, Kwo PY, Sulkowski M, Brau N, Hernandez D, McPhee F, Wind-Rotolo M, Liu Z, Noviello S, Hughes EA, Yin PD, Schnittman S. 2015. Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64:948-956. http://dx.doi.org/10.1136/gutjnl-2014-307498.
16. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, Mo H, Symonds WT, McHutchison JG, Membreno FE. 2014. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 383:515-523. http://dx.doi.org/10.1016/S0140-6736 (13) 62121-2.
17. Bristol-Myers Squibb Company, Kim S, Gao Q, Yang F. 12 February 2009. Crystalline form of methyl ((1S)-1-(((2S)-2-(5-(4'-(2-((2S)-1-((2S)-2-((methoxycarbonyl) amino)-3-methylbutanoyl)-2-pyrrolidinyl) - 1H-imidazol-5-yl)-4-biphenylyl)-1H-imidazol-2-yl)-1-pyrrolidinyl) carbonyl)-2-methylpropyl) carbamate dihydrochloride salt. World Intellectual Property Organization. International publication number WO 2009/020828 A1-12.
18. Peng B, Yu M, Xu S, Lee YJ, Tian Y, Yang H, Chan K, Mo H, McHutchison J, Delaney W, IV, Cheng G. 2013. Development of robust hepatitis C virus genotype 4 subgenomic replicons. Gastroenterology 144:59-61. http://dx.doi.org/10.1053/j.gastro.2012.09.033.
19. Horscroft N, Bellows D, Ansari I, Lai VC, Dempsey S, Liang D, Donis R, Zhong W, Hong Z. 2005. Establishment of a subgenomic replicon for bovine viral diarrhea virus in Huh-7 cells and modulation of interferonregulated factor 3-mediated antiviral response. J Virol 79:2788-2796. http://dx.doi.org/10.1128/JVI.79.5.2788-2796.2005.
20. Ladner S, Otto M, Barker C, Zaifert K, Wang G, Guo J, Seeger C, King R. 1997. Inducible expression of human hepatitis B virus (HBV) in stably transfected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV replication. Antimicrob Agents Chemother 41:1715-1720.
21. Cheng G, Chan K, Yang H, Corsa A, Pokrovskii M, Paulson M, Bahador G, Zhong W, Delaney W, IV. 2011. Selection of clinically relevant protease inhibitor-resistant viruses using the genotype 2a hepatitis C virus infection system. Antimicrob Agents Chemother 55:2197-2205. http://dx.doi.org/10.1128/AAC.01382-10.
22. Feng JY, Cheng G, Perry J, Barauskas O, Xu Y, Fenaux M, Eng S, Tirunagari N, Peng B, Yu M, Tian Y, Lee YJ, Stepan G, Lagpacan LL, Jin D, Hung M, Ku KS, Han B, Kitrinos K, Perron M, Birkus G, Wong KA, Zhong W, Kim CU, Carey A, Cho A, Ray AS. 2014. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 58:1930-1942. http://dx.doi.org/10.1128/AAC.02351-13.
23. Yu M, Corsa AC, Xu S, Peng B, Gong R, Lee YJ, Chan K, Mo H, Delaney W, IV, Cheng G. 2013. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons. Antiviral Res 100:439-445. http://dx.doi.org/10.1016/j.antiviral.2013.08.018.
24. Yu M, Peng B, Chan K, Gong R, Yang H, Delaney W, IV, Cheng G. 2014. Robust and persistent replication of genotype 6a hepatitis C virus replicon in cell culture. Antimicrob Agents Chemother 58:2638-2646. http://dx.doi.org/10.1128/AAC.01780-13.
25. Robinson M, Yang H, Sun SC, Peng B, Tian Y, Pagratis N, Greenstein AE, Delaney WE, IV. 2010. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a. Antimicrob Agents Chemother 54:3099-3106. http://dx.doi.org/10.1128/AAC.00289-10.
26. Yang H, Robinson M, Corsa AC, Peng B, Cheng G, Tian Y, Wang Y, Pakdaman R, Shen M, Qi X, Mo H, Tay C, Krawczyk S, Sheng XC, Kim CU, Yang C, Delaney WE, IV. 2014. Preclinical characterization of the novel hepatitis C virus NS3 protease inhibitor GS-9451. Antimicrob Agents Chemother 58:647-653. http://dx.doi.org/10.1128/AAC.00487-13.
27. Friebe P, Lohmann V, Krieger N, Bartenschlager R. 2001. Sequences in the 5' nontranslated region of hepatitis C virus required for RNA replication. J Virol 75:12047-12057. http://dx.doi.org/10.1128/JVI.75.24.12047-12057.2001.
28. Prichard MN, Aseltine KR, Shipman C, Jr. 1993. MacSynergy II, version 1.0. University of Michigan, Ann Arbor, MI.
29. Prichard MN, Shipman C, Jr. 1996. Analysis of combinations of antiviral drugs and design of effective multidrug therapies. Antivir Ther 1:9-20.
30. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
31. Naggie S, Sulkowski MS. 2012. Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. Gastroenterology 142:1324-1334. http://dx.doi.org/10.1053/j.gastro.2012.02.012.
32. Kohli A, Kapoor R, Sims Z, Nelson A, Sidharthan S, Lam B, Silk R, Kotb C, Gross C, Teferi G, Sugarman K, Pang PS, Osinusi A, Polis MA, Rustgi V, Masur H, Kottilil S. 2015. Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 15:1049-1054. http://dx.doi.org/10.1016/S1473-3099 (15) 00157-7.
33. Gane EJ, Hyland RH, An D, Svarovskaia E, Pang PS, Brainard D, Stedman CA. 2015. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 149:1454-1461. e1. http://dx.doi.org/10.1053/j.gastro.2015.07.063.
34. Lam AM, Espiritu C, Bansal S, Micolochick Steuer HM, Niu C, Zennou V, Keilman M, Zhu Y, Lan S, Otto MJ, Furman PA. 2012. Genotype and subtype profilingof PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob Agents Chemother 56:3359-3368. http://dx.doi.org/10.1128/AAC.00054-12.